<table id="table19" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 19: Summary of Virologic Failures<sup>a</sup> at Week 96 in Study AI424-089: Comparison of Ritonavir Boosted REYATAZ vs. Unboosted REYATAZ: Randomized Patients</caption>
<col span="1" width="54%"></col>
<col span="1" width="23%"></col>
<col span="1" width="23%"></col>
<tbody>
<tr>
<th colspan="1"> </th>
<th colspan="1">
<content stylecode="bold">REYATAZ 300 mg +<br/>ritonavir 100 mg </content>
</th>
<th colspan="1">
<content stylecode="bold">REYATAZ 400 mg</content>
</th>
</tr>
<tr>
<th colspan="1">
<content stylecode="bold">(n=95)</content>
</th>
<th colspan="1">
<content stylecode="bold">(n=105) </content>
</th>
</tr>
<tr>
<td>Virologic Failure (≥50 copies/mL) at Week 96  </td>
<td>15 (16%)</td>
<td>34 (32%)</td>
</tr>
<tr>
<td>Virologic Failure with Genotypes and Phenotypes Data</td>
<td>5</td>
<td>17</td>
</tr>
<tr>
<td>Virologic Failure Isolates with ATV-resistance at Week 96 </td>
<td>0/5 (0%)<sup>b</sup>
</td>
<td>4/17 (24%)<sup>b</sup>
</td>
</tr>
<tr>
<td>Virologic Failure Isolates with I50L Emergence at Week 96<sup>c</sup>
</td>
<td>0/5 (0%)<sup>b</sup>
</td>
<td>2/17 (12%)<sup>b</sup>
</td>
</tr>
<tr>
<td>Virologic Failure Isolates with Lamivudine Resistance at Week 96</td>
<td>2/5 (40%)<sup>b</sup>
</td>
<td>11/17 (65%)<sup>b</sup>
</td>
</tr>
</tbody>
</table>